Singapore to start human clinical trials for potential Covid-19 treatment

Singapore will embark on human clinical trials next week on 23 healthy individuals for a potential treatment for Covid-19, The Strait Times reports.

The phase one trial, developed by Singapore-based biotechnology company Tychan, will be conducted by the SingHealth Investigational Medicine Unit and take about six weeks.

It is meant to determine the safety and effectiveness of TY027, a monoclonal antibody or immune system protein that specifically targets Sars-CoV-2, the virus that causes Covid-19, said Tychan in a statement on Wednesday (June 10).

TY027 is being explored for the treatment of Covid-19 patients by slowing the progression of the disease and speeding up recovery, as well as potentially to provide temporary protection against infection, the company said.